ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant...
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the data from Phase 1 and Phase 2 clinical studies of IBI363, first-in-class PD-1/IL-2α-bias bispecific antibody fusion...
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
NANJING, China, May 31, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide plus platinum-based chemotherapy for treatment-naive patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The results were featured in an oral session...
Duke-NUS celebrates 20 years of medical innovation with largest ever graduating class
Duke-NUS Medical School's Class of 2025 graduates 121 medical and doctoral students, including MDs, MD-PhDs, PhDs, and masters' degrees Landmark first batch of Masters in Patient Safety and Healthcare Quality graduates, unique to Southeast Asia Inaugural graduates from conditional admissions pathways with NUS and SUTD 41% of MD and MD-PhD...
CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world’s first circular RNA drug being administrated in patients
SHANGHAI, May 31, 2025 /PRNewswire/ -- Shanghai CirCode Biomed Co. Ltd. (CirCode), an innovative biotech company pioneering circular RNA therapies, recently announced that its leading pipeline HM2002 received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for ischemic heart disease on May 30, 2025. With the...
Illuminating ctDNA-MRD: Gene Solutions’ K-CONNECT APAC 2025 Sparks Regional Collaboration in Precision Oncology
DA NANG, Vietnam, May 31, 2025 /PRNewswire/ -- May 9-11, 2025, Gene Solutions, a pioneer in AI-driven precision oncology hosted K-CONNECT APAC 2025, a pivotal summit uniting over 100 distinguished oncologists and molecular biologists from nine Asia-Pacific countries. — This landmark event marked a significant milestone in advancing precision oncology, fostering collaboration, and driving innovation in the fields of circulating tumor...
Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)
SHANGHAI, May 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name: MAILISHENG, R&D code: 8MW0511) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing approval by National Medical Products Administration (NMPA). MAILISHENG is Mabwell's first commercialized innovative drug, and is the first launched novel...
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application...
Preclinical data with BBT002 demonstrate its best-in-disease potential for improved efficacy and dosing convenience across respiratory, dermatology, and gastroenterology indications Interim safety and pharmacokinetic data from BBT002-01 study anticipated in Q1 2026 The clearance of BBT001-01 study expands the clinical development territory of BBT001 beyond Australia into the United States Bambusa...
Sold out in 3 minutes! How a Sri Lankan streamer masters Chinese e-commerce live streaming?
BEIJING, May 30, 2025 /PRNewswire/ -- Finding Answers in China from China.org.cn:   How did a bottle of chili paste from Sri Lanka make its way overseas and go viral in a Chinese live streaming? And how did a traditional handmade stool help revive the rural economy in Sri Lanka? What made a live streaming...
GC Biopharma’s Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal
YONGIN, South Korea, May 30, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II), have been published in Genetics in Medicine, an SCIE-indexed journal. Conducted at Samsung Medical Center, the Phase 3 clinical...
Teddy Laboratory (GuanHe Pharmaceuticals) Signs Strategic Cooperation Agreement with LabConnect to Forge a New Landscape in Laboratory Services Collaboration
JOHNSON CITY, Tenn., May 30, 2025 /PRNewswire/ -- Teddy Laboratory, a subsidiary of Tigermed, officially signed a strategic cooperation agreement with LabConnect, LLC, a global leader in central laboratory services. The two parties will jointly build a full-chain laboratory service system covering both China and international markets to accelerate the development...
